KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to 0.37.

  • Gilead Sciences' Equity Ratio rose 910.86% to 0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.37, marking a year-over-year increase of 910.86%. This contributed to the annual value of 0.33 for FY2024, which is 1052.11% down from last year.
  • Gilead Sciences' Equity Ratio amounted to 0.37 in Q3 2025, which was up 910.86% from 0.35 recorded in Q2 2025.
  • Gilead Sciences' Equity Ratio's 5-year high stood at 0.37 during Q3 2025, with a 5-year trough of 0.28 in Q1 2021.
  • In the last 5 years, Gilead Sciences' Equity Ratio had a median value of 0.34 in 2022 and averaged 0.33.
  • The largest annual percentage gain for Gilead Sciences' Equity Ratio in the last 5 years was 1637.69% (2021), contrasted with its biggest fall of 2431.53% (2021).
  • Quarter analysis of 5 years shows Gilead Sciences' Equity Ratio stood at 0.31 in 2021, then rose by 8.31% to 0.34 in 2022, then grew by 9.07% to 0.37 in 2023, then decreased by 10.52% to 0.33 in 2024, then rose by 12.31% to 0.37 in 2025.
  • Its Equity Ratio was 0.37 in Q3 2025, compared to 0.35 in Q2 2025 and 0.34 in Q1 2025.